Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-EGFR/c-Met/c-Met trispecific antibody BG-T187

A trispecific antibody targeting epidermal growth factor receptor (EGFR) and two different epitopes of hepatocyte growth factor receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-EGFR/c-Met/c-Met trispecific antibody BG-T187 simultaneously targets and binds to the extracellular domain of both EGFR and two different epitopes of c-Met expressed on tumor cells, thereby preventing receptor phosphorylation and activation of both EGFR- and c-Met-mediated signaling pathways. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-EGFR x c-MET x c-MET trispecific antibody BG-T187
EGFR x cMET x cMET trispecific antibody BG-T187
EGFR x MET TsAb BG-T187
EGFR/cMET/cMET trispecific antibody BG-T187
EGFRxMET trispecific antibody BG-T187
Code name:BG T187
BG-T187
BGT187
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search